Crowell & Moring LLP
08/19/2025 | Press release | Archived content
Crowell & Moring Represents Halda Therapeutics in Landmark Alliance With VantAI To Discover Next-Generation RIPTAC Medicines
New York - August 19, 2025 : Crowell & Moring represented Halda Therapeutics in a strategic research collaboration, worth over $1 billion in total potential value, with VantAI to discover next-generation RIPTAC (Regulated Induced Proximity Targeting Chimeras) medicines.
This landmark alliance aims to accelerate the discovery and development of selective proximity-based therapies across cancer and immunology indications. The agreement includes upfront payments, research support, success-based development and commercial milestones, and tiered royalties on net sales, with a path to expand the collaboration over time.
Under the partnership, VantAI will leverage its Neo-1 foundation model and NeoLink high-throughput structural proteomics platform to rapidly identify and validate novel, context-specific target-effector pairs. These pairs-across both oncology and immunology-will feed directly into Halda's proprietary RIPTAC development pipeline, which harnesses a distinctive "hold-and-kill" mechanism to achieve potent, cell-selective effects in disease-relevant tissues.
Read more about the deal here.
The Crowell deal team was led by Mark Cooper and included Melissa Paddock, Randa Adra, and Irina Goga.
Crowell & Moring LLP published this content on August 19, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 11, 2025 at 16:07 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]